Inhibition of influenza virus replication via small molecules that induce the formation of higher-order nucleoprotein oligomers

Proceedings of the National Academy of Sciences of the United States of America

Volumn 108, Issue 37, 2011, Pages 15366-15371

  Gerritz, Samuel W ^a   Cianci, Christopher ^a   Kim, Sean ^a   Pearce, Bradley C ^a   Deminie, Carol ^a   Discotto, Linda ^a   McAuliffe, Brian ^a   Minassian, Beatrice F ^a   Shi, Shuhao ^a   Zhu, Shirong ^a   Zhai, Weixu ^a   Pendri, Annapurna ^a   Li, Guo ^a   Poss, Michael A ^b   Edavettal, Suzanne ^b   McDonnell, Patricia A ^b   Lewis, Hal A ^b   Maskos, Klaus ^c   Mor̈tl, Mario ^c   Kiefersauer, Reiner ^c   Steinbacher, Stefan ^c   Baldwin, Eric T ^b   Metzler, William ^b   Bryson, James ^b   Healy, Matthew D ^a   Philip, Thomas ^a   Zoeckler, Mary ^a   Schartman, Richard ^a   Sinz, Michael ^a   Leyva Grado, Victor H ^d   Hoffmann, Hans Heinrich ^d   Langley, David R ^a   Meanwell, Nicholas A ^a   Krystal, Mark ^a   more..

^a BRISTOL MYERS SQUIBB   (United States)

^b BRISTOL MYERS SQUIBB RESEARCH AND DEVELOPMENT   (United States)

^c PROTEROS BIOSTRUCTURES GMBH   (Germany)

^d MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Antiinfluenza; Cooperative inhibition; Oligomerization; Polymerase inhibitor; Protein protein interaction

Indexed keywords

4 ACETAMIDO 5 AMINO 3 (1 ETHYLPROPOXY) 1 CYCLOHEXENE 1 CARBOXYLIC ACID; ANTIVIRUS AGENT; DIMER; ISOXAZOLE; NUCLEOPROTEIN; OLIGOMER; TRIAZOLE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIVIRAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BINDING SITE; COMPLEX FORMATION; CONTROLLED STUDY; CRYSTAL STRUCTURE; DOSE RESPONSE; DRUG BLOOD LEVEL; IC 50; INFLUENZA VIRUS; MAXIMUM PLASMA CONCENTRATION; MOUSE; NONHUMAN; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN FUNCTION; PROTEIN QUATERNARY STRUCTURE; PROTEIN TARGETING; SITE DIRECTED MUTAGENESIS; VIRUS INHIBITION; VIRUS REPLICATION; X RAY CRYSTALLOGRAPHY;

ANIMALS; ANTIVIRAL AGENTS; CRYSTALLOGRAPHY, X-RAY; DISEASE MODELS, ANIMAL; HIGH-THROUGHPUT SCREENING ASSAYS; HYDRODYNAMICS; MICE; MODELS, MOLECULAR; NUCLEOPROTEINS; ORTHOMYXOVIRIDAE; ORTHOMYXOVIRIDAE INFECTIONS; PROTEIN MULTIMERIZATION; PROTEIN STRUCTURE, QUATERNARY; SMALL MOLECULE LIBRARIES; SOLUTIONS; VIRUS REPLICATION;

MUS; ORTHOMYXOVIRIDAE;

EID: 80053089237     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1107906108     Document Type: Article

References (34)

1. Hedlund M, Larson JL, Fang F (2010) Antiviral strategies for pandemic and seasonal influenza. Viruses 2:1766-1781.
2. US Food and Drug Administration (2010) Influenza Virus Vaccine for the 2010-2011 Season. Available at http://www.fda.gov/biologicsbloodvaccines/ guidancecomplianceregulatoryinformation/post-marketactivities/lotreleases/ ucm202750.htm. Accessed August 17, 2011.
3. Fiore AE, et al.; Centers for Disease Control and Prevention (2009) Prevention and control of seasonal influenza with vaccines: Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2009. MMWR Recomm Rep 58(RR-8):1-52.
4. Weinstock DM, Zuccotti G (2006) Adamantane resistance in influenza A. JAMA 295: 934-936.
5. Suzuki H, et al. (2003) Emergence of amantadine-resistant influenza A viruses: Epidemiological study. J Infect Chemother 9:195-200. (Pubitemid 37288281)
6. Balannik V, et al. (2009) Design and pharmacological characterization of inhibitors of amantadine-resistant mutants of the M2 ion channel of influenza A virus. Biochemistry 48:11872-11882.
7. Moscona A (2005) Oseltamivir resistance-disabling our influenza defenses. N Engl J Med 353:2633-2636.
8. Dharan NJ, et al.; Oseltamivir-Resistance Working Group (2009) Infections with oseltamivir- resistant influenza A(H1N1) virus in the United States. JAMA 301:1034-1041.
9. Yen HL, et al. (2006) Importance of neuraminidase active-site residues to the neuraminidase inhibitor resistance of influenza viruses. J Virol 80:8787-8795.
10. Krystal MR, Meanwell NA (2009) Influenza-the case for combination therapy. Curr Opin Investig Drugs 10:746-749.
11. Govorkova EA, Webster RG (2010) Combination chemotherapy for influenza. Viruses 2:1510-1529.
12. Ishihama A, Nagata K (1988) Viral RNA polymerases. CRC Crit Rev Biochem 23:27-76.
13. Resa-Infante P, Jorba N, Coloma R, Ortin J (2011) The influenza virus RNA synthesis machine: Advances in its structure and function. RNA Biol 8:207-215.
14. O'Neill RE, Jaskunas R, Blobel G, Palese P, Moroianu J (1995) Nuclear import of influenza virus RNA can be mediated by viral nucleoprotein and transport factors required for protein import. J Biol Chem 270:22701-22704.
15. Noda T, et al. (2006) Architecture of ribonucleoprotein complexes in influenza A virus particles. Nature 439:490-492. (Pubitemid 43152841)
16. Cros JF, García-Sastre A, Palese P (2005) An unconventional NLS is critical for the nuclear import of the influenza A virus nucleoprotein and ribonucleoprotein. Traffic 6:205-213. (Pubitemid 40298155)
17. Noton SL, et al. (2009) Studies of an influenza A virus temperature-sensitive mutant identify a late role for NP in the formation of infectious virions. J Virol 83:562-571.
18. Tao YJ, Ye Q (2010) Influenza A virus nucleoprotein. Influenza: Molecular Virology, eds Wang Q, Tao YJ (Caister Academic, Norfolk, UK), pp 53-68.
19. Kao RY, et al. (2010) Identification of influenza A nucleoprotein as an antiviral target. Nat Biotechnol 28:600-605.
20. Su CY, et al. (2010) High-throughput identification of compounds targeting influenza RNA-dependent RNA polymerase activity. Proc Natl Acad Sci USA 107:19151-19156.
21. Hill AV (1910) Proceedings of the Physiological Society: January 22, 1910. J Physiol 40: iv-vii.
22. Denisov IG, Frank DJ, Sligar SG (2009) Cooperative properties of cytochromes P450. Pharmacol Ther 124:151-167.
23. Ye Q, Krug RM, Tao YJ (2006) The mechanism by which influenza A virus nucleoprotein forms oligomers and binds RNA. Nature 444:1078-1082. (Pubitemid 46018528)
24. Pleschka S, et al. (1996) A plasmid-based reverse genetics system for influenza A virus. J Virol 70:4188-4192. (Pubitemid 26157406)
25. Hanlon AD, Larkin MI, Reddick RM (2010) Free-solution, label-free protein-protein interactions characterized by dynamic light scattering. Biophys J 98:297-304.
26. Takahashi K, et al. (2003) In vitro and in vivo activities of T-705 and oseltamivir against influenza virus. Antivir Chem Chemother 14:235-241. (Pubitemid 37509379)
27. Ng AK-L, et al. (2008) Structure of the influenza virus A H5N1 nucleoprotein: Implications for RNA binding, oligomerization, and vaccine design. FASEB J 22:3638-3647.
28. Chan W-H, et al. (2010) Functional analysis of the influenza virus H5N1 nucleoprotein tail loop reveals amino acids that are crucial for oligomerization and ribonucleoprotein activities. J Virol 84:7337-7345.
29. Ruigrok RWH, Crepin T (2010) Nucleoproteins of negative strand RNA viruses; RNA binding, oligomerisation and binding to polymerase co-factor. Viruses 2:27-32.
30. Eichelberger MC, Hassantoufighi A, Wu M, Li M (2008) Neuraminidase activity provides a practical read-out for a high throughput influenza antiviral screening assay. Virol J 5:109.
31. Neumann G, et al. (1999) Generation of influenza A viruses entirely from cloned cDNAs. Proc Natl Acad Sci USA 96:9345-9350. (Pubitemid 29374757)
32. Kabsch W (2010) XDS. Acta Crystallogr D Biol Crystallogr 66:125-132.
33. Vagin A, Teplyakov A (2010) Molecular replacement with MOLREP. Acta Crystallogr D Biol Crystallogr 66:22-25.
34. Murshudov GN, Vagin AA, Dodson EJ (1997) Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallogr D Biol Crystallogr 53: 240-255. (Pubitemid 27235885)